A paradigm shift: Vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes

Journal of Infectious Diseases

Volumn 209, Issue 6, 2014, Pages 813-815

  Awasthi, Sita ^a   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antibody; genital herpes; glycoprotein D; HSV 2 vaccine; T cells

Indexed keywords

GLYCOPROTEIN D; HERPES VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; LATENT VIRUS INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RECURRENT INFECTION; SEROCONVERSION;

ANTIBODY; GENITAL HERPES; GLYCOPROTEIN D; HSV-2 VACCINE; T-CELLS;

FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HUMANS;

EID: 84895752021     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit658     Document Type: Note

References (35)

1. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008; 86:805-12, A.
2. Schiffer JT, Wald A, Selke S, Corey L, Magaret A. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 2011; 204:554-61.
3. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA2011; 305:1441-9.
4. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509-15.
5. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a metaanalysis. J Infect Dis 2002; 185:45-52.
6. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43.
7. Wald A. Genital HSV-1 infections. Sex Transm Infect 2006; 82:189-90.
8. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204: 595-603.
9. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008; 322: 268-71.
10. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor.N Engl JMed 1991; 324:1247-52.
11. Ashley RL, Dalessio J, Burchett S, et al. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest 1992; 90:511-4.
12. Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T. Viral and cellular contributions to herpes simplex virus entry into the cell. Curr Opin Virol 2012; 2:28-36.
13. Huber MT, Wisner TW, Hegde NR, et al. Herpes simplex virus with highly reduced gD levels can efficiently enter and spread between human keratinocytes. J Virol 2001; 75:10309-18.
14. Parr MB, Parr EL. Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice. Immunology 2000; 101:126-31.
15. Parr EL, Parr MB. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 1997; 71:8109-15.
16. Bourne N, Pyles RB, Bernstein DI, Stanberry LR. Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol 2002; 83: 2797-801.
17. Awasthi S, Lubinski JM, Shaw CE, et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011; 85:10472-86.
18. Parr MB, Parr EL. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J Virol 1998; 72: 2677-85.
19. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012; 491:463-7.
20. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009; 10: 524-30.
21. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282: 331-40.
22. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-61.
23. Garland SM, Lee TN, Ashley RL, Corey L, Sacks SL. Automated microneutralization: method and comparison with Western blot for type-specific detection of herpes simplex antibodies in two pregnant populations. J Virol Methods 1995; 55:285-94.
24. Bernstein DI, Ashley RL, Stanberry LR, Myers MG. Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines. J Clin Microbiol 1990; 28:11-5.
25. Plotkin SA. Vaccines: correlates of vaccineinduced immunity. Clin Infect Dis 2008; 47:401-9.
26. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65.
27. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123-38.
28. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7.
29. Gershon AA. Symposium on infectious complications of neoplastic disease (part II). Immunoprophylaxis of varicella-zoster infections. Am J Med 1984; 76:672-7.
30. Ludwig B, Kraus FB, Allwinn R, Keim S, Doerr HW, Buxbaum S. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination. Infection 2006; 34:222-6.
31. Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21:337-42.
32. Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008; 197:944-9.
33. LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 1996; 174(suppl 3):S320-3.
34. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-77.
35. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.